Monday's Top Healthcare Stocks To Watch Ahead Of Elections
CORAL GABLES, FL / ACCESSWIRE / November 5, 2018 / It's no secret that technology has facilitated access and directly helped meet consumer needs in a multitude of industries. Healthcare has become the latest market to take full advantage of this trend. With the advent of technology in healthcare, innovation has begun to disrupt the healthcare market in a significant way. According to a paper by PwC called The Digital Healthcare Leap, the new trends are ripe for digital healthcare solutions in developed and emerging markets. As a result, the industry has expanded its focus to non-critical health care services to cater to this changing demand of present-day consumers.
Whether young or old, today's population is looking to adopt new technology, which the consumer is demonstrating strong support for new-age quality healthcare services and taking advantage of the technological developments that play a major role in providing these. Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), AcelRX Pharmaceuticals (ACRX) and Teva Pharmaceutical Industries (TEVA).
Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) announced this morning that as a part of its expansion plans it will enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019. With Premier's acquisition of HealthVue Medical Clinics in August, this could be the next phase of growth for the company. Furthermore, the Company expects to provide additional updates on acquisitions in Q4-18 and Q1-19. Premier Health Group, Inc. (PHGRF) (PHGI) is actively reviewing a pipeline of additional pharmacy partners, which include bricks and mortar locations for acquisition and strategic new retail opportunities for pharmacies. "It is our position that the emergence of technology such as the ability for patients to electronically send their prescription(s) to a pharmacy for fulfillment and pick up at a later time or delivery directly to them at home or work will result in increased patient and consumer enrollment in apps that offer this type of functionality," added Dr. Hamza.
Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) entered the primary care clinic and healthcare technology business via the HealthVue transaction and obtained access to a group of four Greater Vancouver-based fully integrated, paperless and electronic-medical-record-based medical clinics with a 10-year history, 22 healthcare professionals and over 100,000 active patients.
For More Information On Premier Health Group, Click Here
AcelRX Pharmaceuticals (ACRX) is a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings. Last week AcelRX provided a business update and reported its third quarter 2018 financial results. This included updates on both its FDA approval of DSUVIA™ as well as the company's financial results for the quarter.
For the third quarter of 2018 net loss was $12.5 million, or $0.21 per basic and diluted share, compared to $13.0 million, or $0.28 per basic and diluted share, for the third quarter of 2017. Net loss for the first nine months of 2018 was $34.6 million, or $0.64 basic and diluted net loss per share, compared to $41.6 million, or $0.91 basic and diluted net loss per share, for the prior year period.
"The FDA's previously announced approval of DSUVIA is a notable achievement for all AcelRx stakeholders, which we anticipate will lead to improved care for patients in acute pain," said Vince Angotti, Chief Executive Officer of AcelRx. "Our third-quarter results demonstrate sustained discipline in our financial management, which we expect to continue as we plan for the commercial launch of DSUVIA, targeted for the first quarter of next year," continued Angotti.
For More Information On AcelRX, Click Here
Teva Pharmaceutical Industries (TEVA) raised its earnings outlook for 2018 last week and said it was seeing "very good signs of a successful launch" for its long-awaited migraine treatment Ajovy. Ajovy suffered a setback in October when Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, said it will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude Teva's treatment.
"Our restructuring plan has already resulted in a significant cost reduction of $1.8 billion in the first nine months of the year and we are on track to achieve a reduction of $3.0 billion by the end of 2019 while continuing to pay down our debt," Teva Chief Executive Kare Schultz said. (Reporting by Tova Cohen Editing by Steven Scheer).
Shares were up sharply during the opening moments of the market on Monday morning as Teva stock hit highs of $23.34.
For More Information On Teva, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com
